Thomas Aaberg Jr, MD

Aaberg is chief medical officer at Neurotech Pharmaceuticals. He is a retina specialist with Retina Specialists of Michigan, and an assistant clinical professor at Michigan State University in East Lansing.

Articles by Thomas Aaberg Jr, MD

A roadmap to preserving the prime years of patients diagnosed with MacTel

ByThomas Aaberg Jr, MD

October 18th 2022

According to Thomas Aaberg, MR, the novel therapy is geared to treat rare, debilitating eye disease.

Thomas Aaberg Jr, MD

Articles by Thomas Aaberg Jr, MD

A roadmap to preserving the prime years of patients diagnosed with MacTel

Latest Updated Articles

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

Ophthalmic innovation by the decades: The 2000s

EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME

FDA approves Rayner’s RayOne EMV Toric intraocular lens

The Residency Report: Social media and the modern ophthalmologist

Avisi Technologies’ investigational device exemption for VisiPlate approved by FDA